Current Management of Acute Lymphoblastic Leukemia in Adults | CancerNetwork
Intensive remission chemotherapy followed by post‑remission consolidation and maintenance therapies has achieved complete remission rates of 75 % to 90 % and 3‑year survival rates of 25 % to 50 % in adults with acute lymphoblastic leukemia (ALL).
Intensive remission chemotherapy followed by post‑remission consolidation and maintenance therapies has achieved complete remission rates of 75 % to 90 % and 3‑year survival rates of 25 % to 50 % in adults with acute lymphoblastic leukemia (ALL). These results, although promising, are still less favorable than those achieved in childhood ALL. However, various novel experimental and clinical approaches show promise for improving cure rates. Also, specific therapies directed at high‑risk subgroups with ALL are beginning to emerge. Detection of specific chromosomal abnormalities at diagnosis identifies patients who are at risk of failing to achieve remission, as well as those who are likely to have short, intermediate, or prolonged disease‑free intervals after successful remission induction. Such prognostic information may, ultimately, be used to assign risk categories and to individualize post‑remission therapy.
These outcomes provide a benchmark for assessing the efficacy of newer therapies and underscore the need for risk‑adapted treatment strategies to achieve cure in adult ALL.
Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.
Related signals
- Acute Myeloid Leukemia Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf
- Recent advances on blinatumomab for acute lymphoblastic leukemia
- NCT05800210: Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Acute Lymphoblastic Leukemia
- Advancing the Diagnosis of Non‑Hodgkin Lymphoma Through Next‑Generation Sequencing in Developing Countries: An Evaluation of Progress — A Narrative Review
- The Evolving Therapeutic Revolution in Adult Acute Lymphoblastic Leukemia